Hims & Hers: Soleil Boughton proposes $64.1K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Hims & Hers Health, Inc. officer Soleil Boughton reported a proposed sale of 3,458 Class A shares, with an approximate sale date of November 17, 2026, and aggregate market value of $64,076.74. The shares were acquired from the issuer through restricted stock vesting on November 15, 2026, as compensation. The notice lists a Rule 10b5-1 plan adoption date of May 21, 2026. It also records six Class A sales during the preceding three months, including 25,111 shares on August 19, 2026, and 3,462 shares on October 28, 2026. Fidelity Brokerage Services LLC is named as the broker. Wade Moss signed as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Soleil Boughton.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Vesting financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much were the gross proceeds from Soleil Boughton's August 19, 2026 HIMS sale?
What Rule 10b5-1 plan date is listed for Soleil Boughton's proposed HIMS sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.